Navigation Links
DaVita Clinical Research Completes Record Number of Renal Trials in 2007
Date:5/8/2008

Nation's Largest Renal Research Network Completes 13 Phase-I Clinical

Trials; Reports Another 34 Active Trials in Late Stage Development

EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I clinical trials in 2007 and has another 34 active trials in late stage drug development-a company record.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

DCR(R), through its commitment to quality, timely and accurate clinical trials, plays a valuable role by partnering with physicians, pharmaceutical and biotechnology companies to develop and progress new drug therapies for patients diagnosed with chronic kidney disease (CKD). The increase in completed and late stage trials also serves as an indication of continued innovation and investment for end stage renal disease (ESRD) research.

"The recent DaVita Clinical Research accomplishments can be attributed to our continuous research quality index measurements and commitment to service excellence," said Chris Rucker, DCR Vice President and General Manager. "These values serve as a catalyst for our research objectives, and allow us to participate in the advancement of renal knowledge and practice."

DCR has nearly two decades of experience in conducting Phase I-IV clinical trials, and is the nation's largest renal research network dedicated to providing and supporting clinical and data research. DCR provides Phase-I renal studies services including renal, Hepatic, CV, Dermatology and Endocrine subjects, Pharmacokinetics, Pharmacodynamics and drug interactions. Phase II- IV renal studies services include pre ESRD and ESRD subjects, clinical efficacy and safety, special populations and post marketing studies.

"Since departing full-time academics for private practice, DaVita Clinical Research has helped me to continue my clinical research efforts," said Robert I. Lynn, M.D. of Nephrology & Hypertension Associates. "The staff locates high quality studies and makes it easier to do clinical trials in DaVita(R) facilities. They are friendly, responsive and supportive, and DaVita Clinical Research really does work with you not only to get a research effort 'off the ground,' but also to help it develop and prosper."

DaVita and DaVita Clinical Research are registered trademarks of DaVita Inc. All other trademarks are the properties of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,300 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information about DaVita and its kidney education programs, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Clinical Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
2. Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
3. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
8. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
9. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
10. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
11. Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):